Prime Capital Investment Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

Prime Capital Investment Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$74.43 - $92.22 $159,652 - $197,811	-2,145 Reduced 42.79%	2,868 $236,000
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $331,636 - $391,743	-3,957 Reduced 44.11%	5,013 $437,000
Q4 2023 Jan 24, 2024	SELL	$76.22 - $98.51 $18,369 - $23,740	-241 Reduced 2.62%	8,970 $864,000
Q3 2023 Nov 09, 2023	BUY	$85.07 - $94.48 $187,494 - $208,233	2,204 Added 31.45%	9,211 $814,000
Q2 2023 Aug 08, 2023	BUY	$86.68 - $100.3 $17,336 - $20,060	200 Added 2.94%	7,007 $607,000
Q1 2023 May 05, 2023	BUY	$87.74 - $117.27 $597,246 - $798,256	6,807 New	6,807 $661,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Prime Capital Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Prime Capital Investment Advisors, LLC with notifications on news.